Ventrus Biosciences gets NoA for VEN 307 patent from USPTO
The patent entitled, ‘Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker" is still pending. Ventrus chairman and CEO Russell Ellison said this is a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.